Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review

Targeting the immune system, especially the PDL-1/PD-1 axis, has significantly improved the outcomes of metastatic lung cancer patients. However, only a portion of patients will benefit significantly from PD(L)1 therapeutics alone or in combination with either chemotherapy or anti-CTLA4 antibody. It...

Descripción completa

Detalles Bibliográficos
Autores principales: Khwaja, Raida M., Chu, Quincy S.-C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871041/
https://www.ncbi.nlm.nih.gov/pubmed/35200543
http://dx.doi.org/10.3390/curroncol29020043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871041/
https://www.ncbi.nlm.nih.gov/pubmed/35200543
http://dx.doi.org/10.3390/curroncol29020043

Ejemplares similares